Axcella Health (NASDAQ:AXLA) initiated with Buy rating and $10 (115% upside) price target at BTIG Research.
Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating and $9 (56% upside) price target at BTIG. Shares up 2% premarket.
Y-mAbs Therapeutics (NASDAQ:YMAB) initiated with Buy rating at Janney Montgomery.
Mirati Therapeutics (NASDAQ:MRTX) upgraded to Overweight with a $116 (36% upside) price target at JPMorgan.
ResMed (NYSE:RMD) upgraded to Outperform with a $200 (29% upside) price target at Oppenheimer. Shares up 2% premarket.
Seattle Genetics (NASDAQ:SGEN) upgraded to Buy with a $175 (28% upside) price target at Guggenheim.
Cerner (NASDAQ:CERN) downgraded to Hold with a $72 (4% upside) price target at SunTrust.
NovoCure (NASDAQ:NVCR) downgraded to Market Perform with a $78 price target at Oppenheimer. Shares down 2% premarket.
PRA Health (NASDAQ:PRAH) downgraded to Market Perform at William Blair.
PolarityTE (NASDAQ:PTE) downgraded to Market Perform at Oppenheimer.
https://seekingalpha.com/news/3567579-guggenheim-likes-seattle-genetics-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.